Abstract: Disclosed herein is a method for authenticating a user for access to a vehicle, including: a. receiving an access request, b. in response to the access request, recording an image, c. extracting at least one facial feature of the image, d. receiving a template, e. generating an access signal indicative of whether the user has access based on a comparison of the at least one facial feature and the template, and f. outputting the access signal.

Abstract: An apparatus, for automated sampling from vessels that may be under a high pressure, is achieved by a specific construction with multiple multiport valves. A method of automated sampling can be used with the apparatus.

Abstract: A hand-pulled instrument, such as an accordion, typically has a sound post (or reed post) on which several reed plates are mounted. The reed plate usually has two oblong openings. Each opening relates to an elongated reed, which is widened at one of its two longitudinal ends for attachment to the reed plate. The opposite long end of the reed is not further fixed. The reed can be made to vibrate in a way that it partially swings into the associated opening. If air flows through the opening, in particular, due to a movement of a bellows of the hand-pulled instrument, such vibration can be generated, and in this way, an audible tone is produced. The reeds are usually attached to the reed plate with a rivet.

Abstract: The present invention relates to an antibody variable domain, which specifically binds to IL-31, to multispecific antibodies comprising one or two of said antibody variable domains and at least one further binding domain that specifically binds to a target different from IL-31. The present invention further relates to a nucleic acid or two nucleic acids encoding said antibody variable domain or said multispecific antibody, vector(s) comprising said nucleic acids or said nucleic acids, host cell(s) comprising said nucleic acid or said nucleic acids or said vector(s), and a method of producing said antibody variable domain or said multispecific antibody. Additionally, the present invention relates to pharmaceutical compositions comprising said antibody variable domain or said multispecific antibody and to methods of use thereof.

Abstract: The present invention relates to novel antibody variable domain combinations with advantageous properties.

Abstract: The present invention relates to a multispecific antibody comprising two antibody-based binding domains, which specifically binds to mesothelin (MSLN-BD); and at least one antibody-based binding domain, which specifically binds to CD3 (CD3-BD); wherein said multispecific antibody does not comprise an immunoglobulin Fc region polypeptide, and wherein each of said MSLN-BD binds to mesothelin (MSLN) with a monovalent dissociation constant (KD) in the range of from 0.5 to 20 nM, when measured by SPR. The present invention further relates to nucleic acid sequence(s) encoding said multispecific antibody, vector(s) comprising aid nucleic acid sequence(s), host cell(s) comprising said nucleic acid sequence(s) or said vector(s), and a method of producing said multispecific antibody. Additionally, the present invention relates to pharmaceutical compositions comprising said multispecific antibody and methods of use thereof.

Abstract: The present invention relates to a multispecific antibody comprising at least one CD137 binding domain and at least one PDL1 binding domain, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid encoding said multispecific antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said multispecific antibody.

Abstract: The present invention relates generally to an isolated antibody which specifically binds human CD137, and pharmaceutical compositions and methods of use thereof, a nucleic acid comprising a nucleotide sequence encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.

Abstract: The present invention relates to a multispecific antibody comprising at least one domain specifically binding to a tumor-associated immune checkpoint antigen with low affinity, and at least one domain specifically binding to a tumor-associated antigen (TAA), and pharmaceutical compositions and methods of use thereof.

Abstract: The present invention relates to novel antibodies that are specific for human CD3, in particular for the CD3? domain.

Abstract: The present invention relates to novel antibody variable domain combinations with advantageous properties.

Abstract: The present invention relates to novel antibodies that are specific for human serum albumin (HSA).

Abstract: The present invention relates to novel antibodies that are specific for human CD3, in particular for the CD3? domain.

Abstract: The present invention relates to an isolated multispecific antibody comprising a first domain specifically binding TNF? and a second domain specifically binding IL-17A and, optionally, a third domain specifically binding human serum albumin. The present invention furthermore relates to an isolated antibody which specifically binds human IL-17A, Additionally, the present invention further relates to methods of use of said antibodies, pharmaceutical compositions and methods of use thereof, and a kit comprising said antibodies. The present invention also relates to a nucleic acid comprising a nucleotide sequence encoding said antibodies, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibodies.

Abstract: The present invention relates to an isolated antibody which specifically binds human CD137, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid comprising a nucleotide sequence encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.

Abstract: The present invention relates generally to an isolated antibody which specifically binds human CD137, and pharmaceutical compositions and methods of use thereof, a nucleic acid comprising a nucleotide sequence encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.

Abstract: The present invention relates to novel antibodies that are specific for human serum albumin (HSA).

Abstract: The present invention relates to an isolated antibody which specifically binds human PDL 1, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.

Abstract: The present invention relates to novel antibody variable domain combinations with advantageous properties.